Ingevity (NGVT)
(Delayed Data from NYSE)
$38.44 USD
+1.94 (5.32%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $38.46 +0.02 (0.05%) 7:58 PM ET
5-Strong Sell of 5 5
C Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$38.44 USD
+1.94 (5.32%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $38.46 +0.02 (0.05%) 7:58 PM ET
5-Strong Sell of 5 5
C Value D Growth C Momentum D VGM
Zacks News
Ingevity Corporation (NGVT) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Ingevity Corporation (NGVT) delivered earnings and revenue surprises of 33.33% and 9.99%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Ingevity Corporation (NGVT) Q1 Earnings Expected to Decline
by Zacks Equity Research
Ingevity Corporation (NGVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ingevity to Gain From Capa Buyout & Regulation-driven Demand
by Zacks Equity Research
While Ingevity (NGVT) is exposed to cost pressures, and weakness in industrial specialties and oilfield applications, it should gain from the Capa acquisition.
Here's Why You Should Hold Onto Ingevity (NGVT) Stock Now
by Zacks Equity Research
Let's find out why specialty chemicals and materials maker Ingevity (NGVT) is worth retaining at the moment.
Ingevity Provides Update in Response to Coronavirus Outbreak
by Zacks Equity Research
Ingevity's (NGVT) first quarter is going better than anticipated despite modest headwinds from the coronavirus outbreak.
Coronavirus, Tariffs Mar Chemical Specialty Industry Outlook
by Anindya Barman
Weak demand and raw material supply disruptions due to coronavirus as well as hefty trade tariffs pose as headwinds to the chemical specialty industry.
Why Is Ingevity Corporation (NGVT) Down 23.9% Since Last Earnings Report?
by Zacks Equity Research
Ingevity Corporation (NGVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ingevity (NGVT) Authorizes Share Repurchase Worth $500M
by Zacks Equity Research
Ingevity's (NGVT) new authorization provides it with the flexibility to be opportunistic through 2020.
New Strong Sell Stocks for February 6th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Ingevity (NGVT) Q4 Earnings Surpass Estimates, Sales Miss
by Zacks Equity Research
While Ingevity (NGVT) faced challenges from continued macroeconomic pressure in the fourth quarter, it gained from growth in end-use applications.
Ingevity Corporation (NGVT) Q4 Earnings Beat Estimates
by Zacks Equity Research
Ingevity Corporation (NGVT) delivered earnings and revenue surprises of 12.24% and -0.24%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Ingevity Corporation (NGVT) Up 2.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Ingevity Corporation (NGVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Near-Term Prospects Gloomy for Specialty Chemical Stocks
by Anindya Barman
Trade tariffs and raw material cost inflation pose as headwinds to the chemical specialty industry.
Ingevity's (NGVT) Earnings Top Estimates in Q3, Sales Miss
by Zacks Equity Research
While Ingevity (NGVT) faced challenges from weak market conditions in Q3, it gained from the Capa caprolactone acquisition.
Ingevity Corporation (NGVT) Q3 Earnings Beat Estimates
by Zacks Equity Research
Ingevity Corporation (NGVT) delivered earnings and revenue surprises of 2.82% and -1.47%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Ingevity Corporation (NGVT) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Ingevity Corporation (NGVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AXTA vs. NGVT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AXTA vs. NGVT: Which Stock Is the Better Value Option?
Ingevity Corporation (NGVT) Down 20.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Ingevity Corporation (NGVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ICL or NGVT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ICL vs. NGVT: Which Stock Is the Better Value Option?
ICL vs. NGVT: Which Stock Is the Better Value Option?
by Zacks Equity Research
ICL vs. NGVT: Which Stock Is the Better Value Option?
Ingevity's (NGVT) Earnings Beat Estimates in Q2, Sales Lag
by Zacks Equity Research
Ingevity (NGVT) gains from inorganic and organic growth strategy in Q2. The company reaffirms guidance for 2019.
Ingevity Corporation (NGVT) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Ingevity Corporation (NGVT) delivered earnings and revenue surprises of 0.74% and -3.52%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Ingevity Corporation (NGVT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Ingevity Corporation (NGVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ICL vs. NGVT: Which Stock Is the Better Value Option?
by Zacks Equity Research
ICL vs. NGVT: Which Stock Is the Better Value Option?
Ingevity (NGVT) Up 20% in a Year: What's Driving the Stock?
by Zacks Equity Research
Let's take a look into the factors that are working in Ingevity's (NGVT) favor.